1 6. BIBLIOGRAFIA
Bao Q, He B, Pan Y, Tang Z, Zhang Y, Qu L et al. Genetic variation in the promoter of DNMT3B is associated with the risk of colorectal cancer. Int J Colorectal Dis., 2011; 26 (9): 1107-12
Bernasconi P, Barberis M, Baggi F, Passerini L, Cannone M, Arnoldi E, Novellino L, Cornelio F, Mantegazza R.. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol. 2005 Jul;167(1):129-39.
Berrih S, Morel E, Gaud C, Raimond F, Le Brigand H, Bach JF. Anti-AChR antibodies, thymic histology and T cell subset in myasthenia gravis.
Neurology 1984;34:66-71
Blalock A. Thymectomy in the treatment of myastenia gravis, report of 20 cases. J Thorac Surgery 1944;13:16-39;50:64-72
Buckley C, Douek D, NewsomDavis J, Vincent A, Willcox N. Mature, long lived CD4(+) and CD8(+) T cells are generated by the thymoma in myastenia gravis. Ann Neurol. 2001
Burn GL, Svensson l, Sanchez-Blanco C, Saini M, Cope AP. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?FEBS Lett 2011;585:3689-98
Cavalcante P, Barberis M, Cannone M, Baggi F, Antozzi C, Maggi L, Cornelio F, Barbi M, Didò P, Berrih-Aknin S, Mantegazza R, Bernasconi P.Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. Neurology. 2010 Apr 6;74(14):1118-26
2 Cavalcante P, Serafini B, Rosicarelli B, Maggi L, Barberis M, Antozzi C, Berrih-Aknin S, Bernasconi P, Aloisi F, Mantegazza R. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus”. Ann Neurol.
2010 Jun;67(6):726-38.
Chen Z et al. Single nucleotide polymorphism in DNMT3B promoter and the risk of idiopathic thrombocytopenic purpura in Chinese population. J Clin Immunol 28 (5) ,399-404
Coppedè F, Zitarosa MT, Migheli F, Lo Gerfo A, Bagnoli S, Dardano A, Nacmias B, Mancuso M, Monzani F, Siciliano G, Sorbi S, Migliore L.
DNMT3B promoter polymorphisms and risk of late onset Alzheimer’s disease. Curr Alzheimer Res 2012
Coppedè F, Ricciardi R, Denaro M, De Rosa A, Provenzano C et al.
Association of the DNMT3B -579G>T polymorphism with risk of thymomas in patients with myasthenia gravis. Plos One 2013; 8 (11)
Dale H, Pharmacology and nerve-endings (Walter Ernest Dixon Memorial Lecture): section of therapeutics and pharmacology). Proc R med 1935;
28:319.32
Detterbeck FC, Zeeshan A. Thymoma:current diagnosis and treatment.
ChinMed J (Engl), 2013;126:2186-91
Dodge JE, Okano M, Dick F et al. Inactivation of DNMT3B in mouse embrionic fibroblasts results in DNA hypomethylation, chromosomal instability and spontaneous immortalization. J Biol Chem 2005; 23:5594- 605
3 Duthie SJ, Folate and cancer:how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Met Dis 2011;34:101-109
El-Shiekh EH, Bessa SS, Abdou SM, El-Refaey WA, 2012. Role of DNA methyltransferase 3° mRNA expression in Egyptian patients with idiopathic thrombocytopenic purpura. Int J Lab Hematol. 34 (4), 369-376.
Fambrough DM, Drachman DB, Satyamurti S. Neuromuscolar junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973;182:293-5
Fujii Y, Hashimoto J, Monden Y, Ito T, Nakahara K, Kawashima Y.
Specific activation of lymphocites against acetylcoline receptor in the thymus in myasthenia gravis. J Immunol 1986;136:887-91
Fujii Y, Monden Y, Nakahara K, Hashimoto Y, Kawashima Y. Antibody to acetylcoline receptor in myasthenia gravis: production by lympocites from thymus or thymoma. Neurology 1984;34:1182-6
Goll MG, Kierpekar F, Maggert KA, Yoder JA, Hsiech CL, Zhang X et al.
Methylation of tRNAAsp by the DNA methyltrasferase homolog. Science 2006; 11:395-398
Hantai D. et al., Congenital Myasthenic Syndroms, in «Current Opinion in Neurology», 2004, 17, 539-551
Hlady RA, et al. 2012 Loss of Dnmt3b function upregulates the tumor modifier ment and accelerates mouse lymphomagenesis. J Clin Invest. 122 (1), 163-177 (3)
4 Hellman A, Chess A. Gene body-specific methylation on the active X chromosome. Science 2007;315:1141-1143
Hoch W, McConville J, Motamura M, Yamanashi Y. Autoantibodies to the receptor tyrosine kinase Musk in patients with myasthenia gravis without acetilcoline antibodies. Nat Med 2001;7:365-8
Hong YS, Lee HJ, You CH, Roh MS, Kwak JY, Lee MJ, Kim JY. DNMT3b 39179GT polymophism and the risk of adenocarcinoma of the colon in Koreans.Biochem Genet. 2007; 45 (3-4): 155-63
Huidobro C, Fernandez AF, Fraga MF. The role of genetics in the establishment and maintenance of the epigenome. Cell Mol Life Sci 2013;
70:1543-44
Leite Mi, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP et al. IgG1 antibodies to acetylcholine receptors in sieronegative myastenia gravis.
Brain 2008; 131.1940-52
Jolly F. Ueber myasthenia gravis pseudoparalytica. Berl klin Wochenschr 1895; 32:1-7
Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;; 13:484-492
Lee S J, Jeon H S, Jang JS, Park SH, Lee GY, Lee BH et al. DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis, 2005; 26 (2): 403-9
5 Liu Z, Wang L, wang LE, Sturgis EM, Wei Q. DNMT3B gene and risk of sqamous cell carcinoma of the head and neck: a case-control study. 2008.
Cancer Letters 268;; 158-165
Mètivier R, Gallais C, Tiffoche C, LePèron C, Jurkowska RZ, Carmouche RP et al. Clinical DNA methylation of a trascriptionally active promoter.
Nature 2008; 452:45-50
Montgomery KG, Mira CP Liu, Diana M Eccles and Ian G Campbell. The DNMT3BC>G promoter polymorphism and risk of breast cancer in a British population: a case-control study. Breast Cancer Res 2004;6;R390- R394
Nam EJ, et al, 2010. The -283C/T polymorphism of the DNMT3B gene influences the progression of joint destruction in rheumatoid arthritis.
Rheumatol Int 30, 1299-12303
Nancy P, Berrih-Aknin S. Differentisl estrogen receptor expression in autoimmune myasthenia gravis. Endocrinolgy 2005; 146:2345-53
Nastuk WI, Strauss AJ, Osserman KE. Search for a neuromuscolar blocking agent in blood of pazients with miastenia gravis. Am J med 1959; 26:394- 409
Norris EH. The timoma and thymic hyperpalsia in Miastenia gravis with observation on the general pathology. Am J cancer 1936,27:241-33
Okamura M, Fujii Y, Shiono H, Inoue M, Minami M, Utsumi T et al.
Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg. 2008;56:143-50
6 Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke B, et al. Anti-LRP4 autoantibodies in AChR and MuSK-antibody-negative myastenia gravis. J Neurolog 2012;259:427-35
Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE et al.
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.
Nature, 2002; 416:552-556
Richardson B, 2003 DNA methylation and autoimmune disease. Clin Immunol, 109, 72-79
Richardson B, 2007. Primer; epigenetics of autoimmunità. Nat Clin Pract Rheumatol 3, 521-527
Richardson BC, Liebling MR, Hudson Jl, 1990. CD4+ cells treated with DNA methylation inhibitors induces autologous B cell differentiation. Clin Immunol Immunopatholog, 55, 368-381
Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q. A novel polymorphism in human cytosine DNMT3B promoter is associated with an increate risk of lung cancer. Cancer Res 2002; 62: 4992-4995
Shen L., Kondo Y, Guo Y et al. Genome-wide profiling of DNA methylation reveals a classo f normally methylated CpG Island promoters.
PloS Genet 2007;3:2023-2036
Simpson JA. Myasthenia Gravis: a new hypothesis. Scoot Med J 1960;5:419-36
Skeie GO, Pandey JP, Aarli JA, Gilhus NE. TNFA and ThFB polymorphisms in myastenia gravis. Arch Neurolog 1999;56:457-61
7 Taberlay PC, Jones PA, 2011. DNA methylation and cancer. Prog Drug Res., 67, 1-23
Tao J, et al, 2008. Decreased DNA methyltransferase 3A and 3B mRNA expression in peripheral blood mononuclear cells and increate plasma SAH concentration in adult patients with idiopathic thrombocytopenic purpura. J Clin Immunol, 28, 432-439
Vandiedonck C, Giraud M, Garchon HJ, Genetics of autoimmune myastenia gravis: the multifacted contribution of the HLA complez. J Autoimmun 2005;25:6-11
Verchurren JJ, Huijbers MG, Plomp JJ, Nicks EH, Molenaar PC, Martinez P, et al. Pathophysiology of myastenia gravis with antibodies to the acetylcholine receptor, muscle specific kinase and LPR4. Autoimmune Rev 2013;12:918-23
Wang XB, Pirskanen R, Giscombe R, Lefvert AK. Two SPSs in the promoter region of the CTLA-4 gene affect binding of trascription factors and are associated with human myastenia gravis. J Intern Med 2008,263:61- 9. Brief Funct Genomics 11 (3), 240-250
Wu H, Tao J, Sun YE, 2012. Regulation and function of mammalian DNA methylation patterns; a genomic perspective
Xiao Y, Word B, Starlard-Davenport A, Haefele A, Lyn.Cook BD, Hammons G. Age and gender affect DNMT3A and DNMT3B expression in human liver. Cell Biol Toxicol 2008;24 (3): 265-72.
8 Ylmaz V, Tuntuncu Y, Baris Hasbal N, Parman Y, Serdaroglu P, Deymeer F et al. Polymorphisms of interferon_gamma, interleukin_10, interleukin-12 genes in myastenia gravis. Hum Immunol 2007;68:544-9
Zhu S, Zhang H, Tang Y, Liu P, Wang J. DNMT3B polymorphism and cancer risk: a meta analysis of 24 case-control studies. Mol Biol Rep 2012;39:4429-4437
Zuklys S, Balciunaite G, Agarwal A, Faslerkan E, Palmer E, Hollander GA.
Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in the autoimmune-polyendocrinopathy- candidiasis-ectodermal dystrophy. J Immunolog. 2000;165:1976-83
9 Desidero ringraziare la Professoressa Lucia Migliore ed il Dott. Fabio Coppedè per avermi dato l’opportunità di poter intraprendere questa esperienza formativa ed avermi aiutato a raggiungere un traguardo fondamentale per la mia vita.
Ringrazio tutti i collaboratori del laboratorio di Genetica medica per la loro disponibilità e gentilezza, in particolare Angela e Maria per avermi supportato ed aiutata durante questo percorso.
Inoltre ringrazio la Dott.ssa Roberta Ricciardi ed il Prof. Alfredo Mussi per aver reso possibile questo lavoro, mettendo a disposizione la casistica in studio.
